Cost-effectiveness of stroke prevention.
暂无分享,去创建一个
[1] K. Kuntz,et al. Is carotid endarterectomy cost-effective? An analysis of symptomatic and asymptomatic patients. , 1996, Circulation.
[2] N. Cook,et al. Implications of small reductions in diastolic blood pressure for primary prevention. , 1995, Archives of internal medicine.
[3] J. Slattery,et al. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST) , 1998, The Lancet.
[4] C. Mulrow,et al. Hypertension in the elderly. Implications and generalizability of randomized trials. , 1994, JAMA.
[5] G Taubes,et al. The (Political) Science of Salt , 1998, Science.
[6] Cholesterol and coronary heart disease: screening and treatment. , 1998, Quality in health care : QHC.
[7] J. Oehlert,et al. Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons , 1997, Annals of Internal Medicine.
[8] W. Jordan,et al. A cost comparison of balloon angioplasty and stenting versus endarterectomy for the treatment of carotid artery stenosis. , 1998, Journal of vascular surgery.
[9] G. Sicard. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or mild (0–29%) carotid stenosis: European Carotid Surgery Trialist' Collaborative Group. Lancet 1991;337:1235-43 , 1992 .
[10] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[11] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[12] J. Ahluwalia,et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. , 1997, Preventive medicine.
[13] S. Glantz,et al. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. , 1997, Circulation.
[14] B. Norrving,et al. Direct Costs of Stroke for a Swedish Population , 1990, International Journal of Technology Assessment in Health Care.
[15] Y. Sekita. Cost-benefit evaluation of comprehensive medical care for cerebral strokes. , 1985, Medical informatics = Medecine et informatique.
[16] M. Weinstein,et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. , 1993, Journal of the American College of Cardiology.
[17] C. Furberg,et al. Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.
[18] G. Rose,et al. Alcohol and Drugs: the Scottish Experience , 1993 .
[19] R. Harwood,et al. Stroke: Epidemiology, Evidence and Clinical Practice , 1999 .
[20] D K Owens,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.
[21] M. Drummond,et al. Assessing the economic value of antihypertensive medicines. , 1992, Journal of human hypertension.
[22] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[23] L. Smeeth,et al. Nicotine replacement therapy for a healthier nation , 1998, British medical journal.
[24] B. Norrving,et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. , 1992, BMJ.
[25] John F. Forbes,et al. The Cost of Stroke to the National Health Service in Scotland , 1992 .
[26] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[27] Evidence-based medicine or medicines-based evidence? , 1998, Annals of the rheumatic diseases.